variety of stimuli. These autocoids result in platelet shape change/aggregation and vascular smooth muscle contraction through interaction with specific membrane receptors (1) . Due to the indistinguishable effects of these agents upon platelets, a common notation has been to label their combined putative receptor as TXA2/PGH2 (2) . However, some studies have suggested that separate platelet receptors exist for the endoperoxide PGH2 and TXA2 (3, 4) . The thromboxane receptor has been postulated to mediate platelet shape change and the endoperoxide receptor has been postulated to mediate aggregation (3). At present, definitive studies demonstrating distinct subtypes of TXA2/PGH2 receptors are lacking.
The short half-life of TXA2 (-90 s) and PGH2 (-5 min) at physiologic pH (5) precludes direct studies of the binding of these substances to their putative receptor(s). However, stable endoperoxide and thromboxane analogues have been developed, radiolabeled, and successfully used in equilibrium binding studies to the human platelet TXA2/PGH2 receptor.
The stable endoperoxide mimetic [3H]U46619' has been used to bind to human platelets but interpretation of the results has been complicated by markedly varying dissociation constants (Kd) and binding capacities (6) (7) (8) . It is possible that U46619 lacks sufficient potency and/or specific activity to be a useful ligand for investigation of TXA2/PGH2 receptor subtypes. Detailed studies of the human platelet TXA2/PGH2 receptor have also been performed with ['25I ]PTA-OH, a stable radioiodinated TXA2 antagonist. Two different groups have re- ported that [125I]PTA-OH binds to a single site with a capacity of -2,000 sites per platelet (9, 10) . Though [1251] PTA-OH has a higher specific activity and greater affinity for the receptor than does [3H]U46619, its properties as an antagonist may make it less than ideal for discriminating between different TXA2/PGH2 agonist binding sites (11) (12) (13) .
Because of the divergent results regarding the affinity and density of TXA2/PGH2 receptors in prior studies of human platelets with [3H]U46619 and [125I]PTA-OH, this study used a novel radioiodinated TXA2 mimetic ligand, [ '25I]BOP, the most potent radiolabeled TXA2/PGH2 agonist yet described (14) . [ HPLC of the product using the system described above and a mobile phase of methanol-0. 1 M ammonium acetate (63:37) at 1 ml/min resulted in elution of ['25I ]BOP at 15 min. The HPLC fractions containing peak levels of radioactivity were pooled and stored at -20'C until use.
Radiolabeled ligands were prepared the day of use by evaporation under nitrogen gas at room temperature and dissolving in the appropriate volume of assay buffer (25 mM Hepes, 150 mM NaCl, 10 IM indomethacin, pH 7.4).
Platelet aggregation and [Ca]i. For aggregation studies washed platelets were prepared by differential centrifugation and resuspended in assay buffer to a final concentration of 2.5 X 108 platelets/ml. Ca2+ was adjusted to a final concentration of I mM. Platelet aggregation was carried out in a platelet ionized calcium aggregometer (model 600; Chrono-Log Corp., Havertown, PA). Washed platelets (475 l1) were added to siliconized glass cuvettes and incubated for 1 min at 370C before the addition of agonist (25 Ml). The aggregation response was observed for 4 min and dose-response curves were constructed. The EC50 value, defined as the concentration of agonist that produced a half-maximal aggregation response at 3 min, was determined from log-logit transformation of the concentration-response curves. was 60±1% (n = 6). The assays were terminated by the addition of4 ml of ice cold assay buffer and immediate vacuum filtration through GF/C glass fiber filters (Whatman Instruments) followed by three additional 4-ml washes with ice-cold assay buffer. (Fig. 2) . Platelet shape change was still evident at concentrations of I-BOP that did not aggregate the platelets. The maximal shape change response was seen at concentrations of 1-2.5 nM. By amplifying the aggregometer signal 20-fold the shape change response was quantified and concentration-response curves were constructed. I-BOP induced shape change with an ECQo of 0.263±.065 nM (n = 6) (Fig. 2) .
Aequorin-loaded platelets aggregated fully in response to I-BOP with no difference in concentration response (data not shown). The maximal [Ca] i induced by 100 nM I-BOP was 6.3 ,gM. The calcium signal at concentrations of I-BOP that resulted in high amplitude shape change but minimal aggregation (1-2.5 nM) was biphasic with the initial signal seen immediately after addition of the agonist followed by a second signal, which preceded aggregation by 2-3 s. Assuming that the initial signal was the most proximate response to I-BOP stimulation, a concentration-response relationship was obtained that closely paralleled that of shape change and that resulted in an EC50 of the initial phase [Ca]i of 0.209±0.024 nM (n = 3) (Fig. 2) .
Binding BOP. An exponential decrease in binding was observed (Fig.   7 ). Linear transformation of the data (Fig. 5, inset) (Table I) . Three antagonists were characterized in the same manner.
Hill coefficients were not significantly different from unity for antagonist competition of either the agonist or antagonist ligand (Table I ). The two most potent of these compounds, ['271]PTA-OH and SQ29,548, were significantly less potent competitors for the TXA2/PGH2 receptor agonist binding site compared with the antagonist binding site (Table I) .
Discussion
This study provides evidence for two distinct TXA2/PGH2 receptor subtypes in human platelets. ['251 ]BOP, the most potent radiolabeled TXA2/PGH2 agonist yet described (14) The potency of I-BOP to stimulate platelet function closely paralleled its affinity for the two binding sites. The EC50 for I-BOP to promote platelet aggregation was 4.4 nM, similar to the lower affinity Kd of 2.3 nM. However, the EC50 for shape change was 263 pM, similar to the higher affinity Kd of 234 pM. Although both platelet aggregation and shape change are calcium dependent phenomena, shape change is dependent on the early redistribution of intracellular calcium stores, whereas aggregation requires the influx ofextracellular calcium. Therefore, the initial increase in intraplatelet calcium ([Ca] i) was assessed simultaneously with the platelet function studies using the photoprotein aequorin. The EC50 for I-BOP to induce the initial [Ca]i was 209 pM, which correlates well with the 263-pM EC50 for shape change and also approximated the high-affinity ['25I]BOP Kd. If one assumes that the I-BOP-receptor interaction follows mass-action law and that the relationship of receptor occupancy to platelet response is linear, then these findings suggest that the two putative receptors may independently mediate platelet aggregation and shape change. This schema is consistent with the notion that there are separate platelet TXA2 and endoperoxide (PGH2) receptors (3, 4) with distinct functions. As suggested by Carmo et al., endoperoxides may be responsible for irreversible platelet aggregation and secretion whereas TXA2 may cause initial platelet shape change and cellular approximation (3 (13) . Antagonists bind with less specificity than do agonists and, in general, with greater capacity. Whereas the antagonist-receptor interaction is thermodynamically favorable, the agonist-receptor interaction is thermodynamically unfavorable but results in a conformational change in the receptor-ligand complex which permits the subsequent cellular response(s) ( 12) . The antagonist lacks the proper "fit" in the receptor to induce the appropriate conformation and thus no response occurs (13) . Therefore, it is not surprising that differences exist in the binding characteristics of the two ligands used in this study.
Low Hill coefficients and curvilinear Scatchard plots do not result exclusively from the presence of multiple receptors. Negative cooperativity within a single receptor population, where receptor affinity increases as the proportion of occupied receptors decreases, also results in concave upward Scatchard plots and low Hill coefficients. One way to distinguish between these two phenomena is to displace the ligand from its binding site using dilution instead ofadding unlabeled competitor (2 1).
If negative cooperativity were present the slope ofthe dissociation curve would be more shallow in the dilution experiment than the competition experiment because the ligand affinity of the receptor increases as a greater proportion of receptor is left unoccupied. This would not be the case for multiple binding sites where the affinity of each independent site does not change with receptor occupancy. In this study dissociation by both competition and serial dilution demonstrates nearly identical dissociation curves. The data strongly suggest that two different receptor populations rather than negative cooperativity is the explanation for the observed complex binding phenomena.
An additional finding ofthe present study is the differences in affinity of the agonist and antagonist compounds at either the agonist or antagonist binding site (represented by [ 
